Fintel reports that on January 2, 2025, Piper Sandler downgraded their outlook for Biogen (NasdaqGS:BIIB) from Overweight to ...

Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Biogen (BIIB) stock slipped as Piper Sandler downgraded the company to neutral from overweight, citing challenges in Alzheimer's drug market. Read more here.

Biogen Inc. (NASDAQ:BIIB – Get Free Report) was the target of a significant decrease in short interest in the month of ...

Several other equities research analysts have also recently commented on BIIB. Wedbush dropped their target price on Biogen from $210.00 to $205.00 and set a “neutral” rating on the stock in a ...

BIIB is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 9.31; value investors ...

Biogen Inc. closed $107.72 short of its 52-week high ($259.93), which the company achieved on January 5th.

Piper Sandler downgraded Biogen (BIIB) to Neutral from Overweight with a price target of $138, down from $315, following a transfer of ...